Evaluation of the efficacy of Vesusten in the treatment of urge urinary incontinence in menopausal and postmenopausal women
Mazitova M.I., Faustova K.V., Antropova E.Yu., Mardieva R.R.
Objective: To evaluate the efficacy of Vesusten in the treatment of urge urinary incontinence in menopausal and postmenopausal women.
Materials and methods: The study included 52 women aged 47 to 56 years. Vesusten was used for the treatment of urge urinary incontinence 3 times a week at a dose of 5 mg intramuscularly (a total of 10 injections). The PPIUS, TUFS scales were used to assess the severity of urge symptoms, and the OAB-q questionnaire was used to assess the patients’ concern about urge symptoms.
Results: Vesusten had a strong positive effect in the form of a decrease in the total urinary frequency scores and severity of urinary urgency on the TUFS scale in all respondents by the 2nd visit; the number of scores continued to decrease by visit 3 (4 weeks after the end of therapy). The daily number of episodes of urge urinary incontinence decreased in 32 study participants (61.5%) to an average of 3.9±1.1 by the 2nd visit and 1.6±2.4 by the 3rd visit, compared with a baseline of 7.1±0.9 episodes. The average PPIUS score at baseline was 3.1 (strong urges with inability to postpone urination). After completion of therapy, the average score decreased to 1.8 at visit 2 (mild to moderate urges) and 0.9 at visit 3 (weak urges). There was a significant decrease in the patients’ concern about overactive bladder symptoms on the OAB-q questionnaire from 66.7 scores at baseline to 16.4 scores by visit 3. No serious adverse events were identified during the study.
Conclusion: Vesusten has a positive effect on urge urinary incontinence in women as it reduces the severity and number of episodes of urge urinary incontinence, as well as patients’ concern about overactive bladder.
Authors’ contributions: Mazitova M.I., Faustova K.V., Antropova E.Yu., Mardieva R.R. – developing the concept and design of the study; Mazitova M.I., Faustova K.V., Antropova E.Yu., Mardieva R.R. – collecting and processing the material; Faustova K.V., Mardieva R.R. – statistical data processing; Faustova K.V., Mazitova M.I. – writing the text; Mazitova M.I., Antropova E.Yu. – editing the article.
Conflicts of interest: Authors declare lack of the possible conflicts of interests.
Funding: The study was carried out without sponsorship.
Patient Consent for Publication: The patients provided an informed consent for the publication of their data.
Authors' Data Sharing Statement: The data supporting the findings of this study are available on request from the corresponding author after approval from the principal investigator.
For citation: Mazitova M.I., Faustova K.V., Antropova E.Yu., Mardieva R.R. Evaluation of the efficacy of Vesusten in the treatment of urge urinary incontinence in menopausal and postmenopausal women.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2024; (9): 149-154 (in Russian)
https://dx.doi.org/10.18565/aig.2024.222
Keywords
urge urinary incontinence
overactive bladder
peptides
References
- Мардиева Р.Р., Мазитова М.И., Мазитов Д.А., Фаустова К.В., Гарафиева С.М. Современный социо-соматический портрет с патологическим климаксом. Вестник современной клинической медицины. 2023; 16(3): 48-53. [Mardieva R.R., Mazitova M.I., Mazitov D.A., Faustova K.V., Garafieva S.M. A Modern socio-somatic portrait of a woman with pathological climax. Bulletin of Contemporary Clinical Medicine. 2023; 16(3): 48-53. (in Russian)]. https://dx.doi.org/10.20969/VSKM.2023.16(3).48-53.
- Федеральная служба государственной статистики (Росстат). Россия в цифрах 2020. Краткий статистический сборник. М.; 2020. 550 с. [Federal State Statistics Service (Rosstat). Russia in figures 2020. Brief statistical compilation. Moscow; 2020. 550 p. (in Russian)].
- Касян Г.Р., Куприянов Ю.А., Ходырева Л.А., Дударева А.А. Синдром гиперактивного мочевого пузыря в клинической практике врача-уролога. Методические рекомендации No 13. M.; 2019. 41 с. [Kasyan G.R., Kupriyanov Yu.A., Khodyreva L.A., Dudareva A.A. Overactive bladder syndrome in the clinical practice of a urologist. Guidelines No. 13. Moscow; 2019. 41 p. (in Russian)].
- Hu J.S., Pierre E.F. Urinary incontinence in women: evaluation and management. Am. Fam. Physician. 2019; 100(6): 339-348.
- Мазитова М.И., Мардиева Р.Р. Генитоуринарный менопаузальный синдром: современный подход к лечению. Гинекология. 2020; 22(6): 16-20. [Mazitova M.I., Mardieva R.R. Genitourinary syndrome of menopause: a modern approach to treatment. Gynecology. 2020; 22(6): 16-20. (in Russian)]. https://dx.doi.org/10.26442/20795696.2020.6.200485.
- Ярмолинская М.И., Колошкина А.В. Алгоритм диагностики и лечения генитоуринарного менопаузального синдрома. Акушерство и гинекология. 2024; 9 (Приложение): 22-36. [Yarmolinskaya M.I., Koloshkina A.V. Algorithm for the diagnosis and treatment of genitourinary syndrome of menopause. Obstetrics and Gynecology. 2024; 9 (Suppl.): 22-36. (in Russian)]. https://dx.doi.org/10.18565/aig.2024.181.
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Недержание мочи. 2020. 41 c. [Ministry of Health of the Russian Federation. Clinical guidelines. Urinary incontinence. 2020. 41 p. (in Russian)].
- Milsom I., Abrams P., Cardozo L., Roberts R.G., Thüroff J., Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87(9): 760-6. https://dx.doi.org/10.1046/j.1464-410x.2001.02228.x.
- Любарская Ю.О., Атдуев В.А. Гиперактивный мочевой пузырь. Ремедиум Приволжье. 2014; 5: 36-41. [Lyubarskaya Yu.O., Atduev V.A. Hyperactive bladder. Remedium Privolzh'e. 2014; (5): 36-41. (in Russian)].
- Liu H.T., Chancellor M.B., Kuo H.C. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur. Urol. 2009; 56(4): 700-6. https://dx.doi.org/10.1016/j.eururo.2008.04.037.
- Fry C.H., Vahabi B. The role of the mucosa in normal and abnormal badder function. Basic Clin. Pharmacol. Toxicol. 2016; 119 Suppl. 3(Suppl. 3): 57-62. https://dx.doi.org/10.1111/bcpt.12626.
- Campbell G.R., Campbell J.H. Ultrastructure of smooth muscle cells inculture. Ch. 4. In: Motta P.M., ed. Ultrastructure of smooth muscle. Boston: Kluwer Academic Publishers; 1990: 79-99.
- Burnstock G. Development of smooth muscle and its innervation. Ch. 20. In: Bulbring E., Brading A.F., Jones A.W., Tomita T., eds. Smooth muscle: An assessment of current knowledge. University of Texas Press; 1981:431-57.
- Fujii S., Konishi L., Katabuchi H., Okamura H. Ultrastructure of smoothmuscle tissue in the female reproductive tract: uterus and oviduct. Ch. 10. In: Motta P.M., ed. Ultrastructure of smooth muscle. Boston: Kluwer Academic Publishers; 1990: 197-220.
- Park E.C., Lim J.S., Kim S.I., Lee S.Y., Tak Y.K., Choi C.W. et al. Proteomic analysis of urothelium of rats with detrusor overactivity induced by bladder outlet obstruction. Mol. Cell. Proteomics. 2018; 17(5): 948-60. https://dx.doi.org/10.1074/mcp.RA117.000290.
- Birder L., Andersson K.E. Urothelial signaling. Physiol. Rev. 2013; 93(2): 653-80. https://dx.doi.org/10.1152/physrev.00030.2012.
- Fry C.H., Young J.S., Jabr R.I., McCarthy C., Ikeda Y., Kanai A.J. Modulation of spontaneous activity in the overactive bladder: the role of P2Y agonists. Am. J. Physiol. Renal Physiol. 2012; 302(11): F1447-54. https://dx.doi.org/10.1152/ajprenal.00436.2011.
- Хавинсон В.Х., Кузник Б.И., Рыжак Г.А. Пептидные биорегуляторы –новый класс геропротекторов. Успехи геронтологии. 2013; 26(1): 20-37. [Khavinson V.Kh., Kuznik B.I., Ryzhak G.A. Peptide bioregulators: the new class of geroprotectors. Advances in Gerontology. 2013; 26(1): 20-37. (in Russian)].
- Hutchinson A., Nesbitt A., Joshi A., Clubb A., Perera M. Overactive bladder syndrome: Management and treatment options. Aust. J. Gen. Pract. 2020; 49(9): 593-8. https://dx.doi.org/10.31128/AJGP-11-19-5142.
- Кривобородов Г.Г., Тур Е.И., Ширин Д.А. Гиперактивный мочевой пузырь: концепция заболевания и подходы к лечению. Медицинский совет. 2021; 4: 121-6. [Krivoborodov G.G., Tur E.I., Shirin D.A. Hyperactive bladder: the concept of disease and paradigms in the treatment. Medical Council. 2021; (4): 121-6. (in Russian)]. https://dx.doi.org/10.21518/2079-701X-2021-4-121-126.
- Hsu F.C., Weeks C.E., Selph S.S., Blazina I., Holmes R.S., McDonagh M.S. Updating the evidence on drugs to treat overactive bladder: a systematic review. Int. Urogynecol. J. 2019; 30(10): 1603-17. https://dx.doi.org/10.1007/s00192-019-04022-8.
- Donoso M.V., Salas C., Sepúlveda G., Lewin J., Fournier A., Huidobro-Toro J.P. Involvement of ETA receptors in the facilitation by endothelin-1 of non-adrenergic non-cholinergic transmission in the rat urinary bladder. Br. J. Pharmacol. 1994; 111(2): 473-82. https://dx.doi.org/10.1111/j.1476-5381.1994.tb14761.x.
- Kinder R.B., Restorick J.M., Mundy A.R. Vasoactive intestinal polypeptide in the hyper-reflexic neuropathic bladder. Br. J. Urol. 1985; 57(3): 289-91.https://dx.doi.org/10.1111/j.1464-410x.1985.tb06346.x.
- Mazur U., Lepiarczyk E., Janikiewicz P., Bossowska A. Somatostatin immunoreactivity within the urinary bladder nerve fibers and paracervical ganglion urinary bladder projecting neurons in the female pig. J. Chem. Neuroanat. 2021; 117: 102007. https://dx.doi.org/10.1016/j.jchemneu.2021.102007.
- Пушкарь Д.Ю., Куприянов Ю.А., Гамидов С.И., Кривобородов Г.Г., Спивак Л.Г., Аль-Шукри С.Х., Лерман Д.М., Гомберг В.Г., Богдан Е.Н., Щукин В.Л., Чибиров К.Х., Гелашвили В.В., Гураль А.К., Кешишев Н.Г., Старосельская М.А., Бастрикова Н.А. Оценка безопасности и эффективности лекарственного препарата Везустен® у пациентов с гиперактивным мочевым. Урология. 2022; 3: 42-51. [Pushkar D.Yu., Kupriyanov Y.A., Gamidov S.I., Krivoborodov G.G., Spivak L.G., Al-Shukri S.Kh., Lerman D.M., Gomberg V.G., Bogdan E.N., Shchukin V.L., Chibirov K.H., Gelashvili V.V., Gural А.К., Keshishchev N.G., Staroselskaia M.A., Bastrikova N.A. Safety and efficiency of Vesusten® for patients with overactive bladder. Urologiia. 2022; (3): 42-51. (in Russian)]. https://dx.doi.org/10.18565/urology.2022.3.42-51.
- Галкина Н.Г., Галкин А.В. Оценка эффективности лекарственного препарата Везустен® у пациенток с гиперактивным мочевым пузырем и хроническим рецидивирующим циститом. Вестник урологии. 2024; 12(3): 36-45. [Galkina N.G., Galkin A.V. Evaluation of the efficacy of Vesusten® in patients with overactive bladder and chronic recurrent cystitis. Urology Herald. 2024; 12(3): 36-45. (in Russian)]. https://dx.doi.org/10.21886/2308-6424-2024-12-3-36-45.
- Малинин В.В., Морозов В.Г. Механизмы пептидной регуляции гомеостаза. Гл. 1. В кн.: Смирнов В.С., ред. Клиническая фармакология тимогена. СПб.; 2004: 7-12. [Malinin V.V., Morozov V.G. Mechanisms of peptide regulation of homeostasis. Ch. 1. In: Smirnov V.S., ed. Clinical pharmacology of thymogen. St. Petersburg; 2004: 7-12. (in Russian)].
- Stoniute A., Madhuvrata P., Still M., Barron-Millar E., Nabi G., Omar M.I. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults. Cochrane Database Syst. Rev. 2023; 5(5): CD003781. https://dx.doi.org/10.1002/14651858.CD003781.pub3.
Received 04.09.2024
Accepted 19.09.2024
About the Authors
Madina I. Mazitova, Dr. Med. Sci., Professor at the Department of Obstetrics and Gynecology, Kazan State Medical Academy, 420012, Russia, Republic of Tatarstan, Kazan, Mushtari str., 11; obstetrician-gynecologist, Clinic «Institute of Health and Longevity», 420111, Russia, Kazan, Kirov lane, 2A, madina13@list.ru,https://orcid.org/0000-0002-9608-2076
Karina V. Faustova, obstetrician-gynecologist, Clinic «Institute of Health and Longevity», 420111, Russia, Kazan, Kirov lane, 2A, +7(918)960-86-68, faustova_rina@mail.ru, https://orcid.org/0000-0001-8702-0159
Elena Y. Antropova, PhD, Associate Professor at the Department of Obstetrics and Gynecology, Kazan State Medical Academy, 420012, Russia, Republic of Tatarstan,
Kazan, Mushtari str., 11; obstetrician-gynecologist, Clinic «Institute of Health and Longevity», 420111, Russia, Kazan, Kirov lane, 2A, +7(903)344-01-32, antropoval@mail.ru,
https://orcid.org/0000-0002-5991-5163
Rezeda R. Mardieva, Teaching Assistant at the Department of Obstetrics and Gynecology, Kazan State Medical Academy, 420012, Russia, Republic of Tatarstan, Kazan, Mushtari str., 11; obstetrician-gynecologist, City Clinical Hospital No. 7 named after M.N. Sadykov, Russia, Kazan; obstetrician-gynecologist,
Clinic «Institute of Health and Longevity», 420111, Russia, Kazan, Kirov lane, 2A, rezedamardieva@gmail.com, https://orcid.org/0000-0003-2568-0121
Similar Articles
